Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dehydroabietic acid is a naturally occurring tricyclic diterpene resin acid primarily derived from the rosin of coniferous trees such as *Pinus* and *Picea* species. It serves as a significant lead compound in medicinal chemistry due to its diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. Mechanistically, dehydroabietic acid acts as a dual agonist of peroxisome proliferator-activated receptors alpha and gamma (PPAR α/γ) and inhibits inflammatory signaling by suppressing the Src-, Syk-, and TAK1-mediated pathways. Preclinical studies have demonstrated its potential against various cancer cell lines (lung, gastric, breast) and multidrug-resistant bacterial strains like *Staphylococcus aureus*. Currently, it is primarily utilized as a research tool and scaffold for drug discovery rather than an approved therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dehydroabietic acid.